Cancer-hunting shark proteins are the future of drug conjugation, says Almac

By Fiona BARRY contact

- Last updated on GMT

The proteins are humanised versions of those found in spiny dogfish sharks (Image: Sergi Balaguer/CC)
The proteins are humanised versions of those found in spiny dogfish sharks (Image: Sergi Balaguer/CC)

Related tags: Monoclonal antibodies, Antibody

Almac is coupling tiny shark proteins to a cancer-killing warhead to develop an oncology drug, saying their small size makes for easy conjugation. 

The collaboration with University of Aberdeen spin-out firm Elasmogen uses humanised antibody-like proteins discovered in spiny dogfish sharks. The companies have named their molecules – which measure one-twelfth the size of a human mAb – Solomer.

Iain James, Almac Discovery Vice President for preclinical and clinical development, told in-Pharmatechnologist.com the shark proteins are useful for drug delivery because their small size allows them to be conjugated to a cytotoxic drug.   

The reason for going for the shark molecules is they are much smaller than mammalian monoclonal antibodies. So the idea is they will penetrate tissue and tumours a lot more efficiently than the large monoclonals.​” 

The proteins – humanised versions of antigen receptor domain antibody fragments (vNARs) – can target particular tumours in the same way as an antibody-drug conjugate, binding to proteins on the surface of cancer cells. 

Almac-Elasmogen collaboration reflects an industry-wide search for smaller targeting proteins, which have advantages over mAbs, said James.  Shark vNARs are recognised as among the smallest known immunoglobulin-based protein scaffolds. 

The proteins in this deal are provided by the University of Aberdeen, while Almac is contributing site-specific conjugation technology which will couple the molecules to the cytotoxic part of the drug. 

The organisations have honed in on an unnamed immuno-oncology target as the core of their collaboration. The compound is in very early preclinical stages, with a preclinical candidate expected to be ready for toxicology tests “within a couple of years.​” 

The parties are sharing development costs, with Almac having an option on all commercialisation revenue.

Elasmogen 

Elasmogen works within the University of Aberdeen’s Scottish Biologics Drug Discovery Facility. It received a US patent in February for its shark-derived vNAR drugs. The original work, which modified vNAR from an immunised shark into a humanised form, received £1.5m ($2.3m) by Scottish Enterprise and by the Biotechnology and Biological Sciences Research Council.

Related news

Show more

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars